Is the intratumor steatosis a novel biomarker for predicting the efficacy of immunotherapy in hepatocellular carcinoma? Li B, Yu D. Hepatology 2022 Jun 15. doi: 10.1002/hep.32616.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Li B, Yu D. Is the intratumor steatosis a novel biomarker for predicting the efficacy of immunotherapy in hepatocellular carcinoma? Hepatology 2022 Jun 15. doi: 10.1002/hep.32616.
PMID: 35702874